2-(5-fluoropyrimidin-2-yl)ethanamine | 944904-83-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(5-fluoropyrimidin-2-yl)ethanamine
• CAS: 944904-83-0
• 化学式: C₆H₈FN₃
• 分子量: 141.148
• InChiKey: TXAYQICBODFXOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(5-fluoropyrimidin-2-yl)ethanamine 、 1-isocyano-3-(trifluoromethoxy)benzene 、 邻羧基苯甲醛 以 甲醇 为溶剂， 以53%的产率得到2-(2-(5-fluoropyrimidin-2-yl)ethyl)-3-oxo-N-(3-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide
  参考文献：
  名称：

  3-Oxoisoindoline-1-carboxamides: Potent, State-Dependent Blockers of Voltage-Gated Sodium Channel Na_V1.7 with Efficacy in Rat Pain Models

  摘要：

  The voltage-gated sodium channel Na(V)1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure activity relationships, and in vitro and in vivo characterization of a novel series of Na(V)1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na(V)1.7 potency, selectivity over Na(V)1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na(V)1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration-dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.

  DOI：

  10.1021/jm300623u

文献信息

• PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1846394A1

  公开（公告）日：2007-10-24
• 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER
  申请人：AstraZeneca AB

  公开号：EP1945631A1

  公开（公告）日：2008-07-23
• [EN] PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLYLAMINOPYRIDINE EMPLOYÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2006082392A1

  公开（公告）日：2006-08-10

  [EN] This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
  [FR] La présente invention concerne de nouveaux composés de Formule (I), des préparations pharmaceutiques desdits composés et leurs méthodes d'application. Lesdits nouveaux composés permettent de traiter les cancers.
• [EN] 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER<br/>[FR] DERIVES 4-(3-AMINOPYRAZOLE)PYRIMIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE TYROSINE KINASES DANS LE CADRE D'UN TRAITEMENT ANTICANCEREUX
  申请人：ASTRAZENECA AB

  公开号：WO2007049041A1

  公开（公告）日：2007-05-03

  [EN] This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
  [FR] Cette invention concerne de nouveaux composés de formule (I), des compositions pharmaceutiques les comprenant ainsi que des procédés pour leur mise en oevre. Ces nouveaux composés fournissent un traitement anticancéreux.